Eli Lilly and Company (NYSE:LLY) Shares Bought by Five Oceans Advisors

Five Oceans Advisors lifted its holdings in Eli Lilly and Company (NYSE:LLYGet Rating) by 6.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,215 shares of the company’s stock after acquiring an additional 69 shares during the period. Five Oceans Advisors’ holdings in Eli Lilly and were worth $394,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Miracle Mile Advisors LLC increased its position in shares of Eli Lilly and by 31.0% in the second quarter. Miracle Mile Advisors LLC now owns 1,997 shares of the company’s stock worth $647,000 after acquiring an additional 473 shares in the last quarter. Capital City Trust Co. FL acquired a new stake in Eli Lilly and during the 2nd quarter valued at $277,000. PDS Planning Inc grew its holdings in Eli Lilly and by 9.1% during the 2nd quarter. PDS Planning Inc now owns 3,344 shares of the company’s stock valued at $1,084,000 after purchasing an additional 278 shares in the last quarter. TKG Advisors LLC grew its holdings in Eli Lilly and by 5.9% during the 2nd quarter. TKG Advisors LLC now owns 7,359 shares of the company’s stock valued at $2,386,000 after purchasing an additional 413 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its holdings in Eli Lilly and by 7.1% during the 2nd quarter. IFM Investors Pty Ltd now owns 137,974 shares of the company’s stock valued at $44,735,000 after purchasing an additional 9,201 shares in the last quarter. Institutional investors and hedge funds own 82.45% of the company’s stock.

Insider Activity

In other Eli Lilly and news, Director Jackson P. Tai purchased 656 shares of the stock in a transaction on Friday, August 12th. The shares were purchased at an average price of $304.19 per share, with a total value of $199,548.64. Following the acquisition, the director now directly owns 62,857 shares of the company’s stock, valued at approximately $19,120,470.83. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Jackson P. Tai bought 656 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The shares were bought at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 89,458 shares of the company’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The disclosure for this sale can be found here. Insiders have sold a total of 328,125 shares of company stock valued at $108,581,151 over the last 90 days. 0.12% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Barclays increased their price objective on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research note on Thursday, July 7th. Citigroup increased their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and increased their price objective for the company from $335.00 to $363.00 in a research note on Thursday. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 7th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $332.19.

Eli Lilly and Price Performance

Eli Lilly and stock traded up $0.90 during trading hours on Friday, hitting $311.77. 41,457 shares of the company traded hands, compared to its average volume of 2,237,822. The firm has a market cap of $296.23 billion, a P/E ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. The firm’s 50-day simple moving average is $314.33 and its two-hundred day simple moving average is $304.45. Eli Lilly and Company has a 1-year low of $220.20 and a 1-year high of $335.33.

Eli Lilly and (NYSE:LLYGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion during the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business’s revenue was down 3.7% on a year-over-year basis. During the same period last year, the business earned $1.87 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were given a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s dividend payout ratio is 62.52%.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.